Program
dencatistat
Its studies are mostly in Lymphoma, B-Cell · Thrombocythemia, Essential, led by Step Pharma, SAS.
Furthest: phase 2, since Jun 30, 20223 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Step Pharma, SAS | 33 open or running | phase 2since Jun 30, 2022 | Jun 30, 2022 | Dec 2026phase 1 · NCT06297525 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2022First study: phase 2 study in Lymphoma, B-CellFirst studyNCT05463263 · 180 planned · United States, France, United Kingdom
- Feb 29, 2024Phase 1 study in Solid TumorNCT06297525 · 70 planned · United States, France, United Kingdom
- Jan 8, 2025Phase 2 study in Thrombocythemia, EssentialNCT06786234 · 50 planned · France, United Kingdom
Ahead
- Dec 2026Primary completion: phase 1 study in Solid TumorNCT06297525
- Dec 2026Primary completion: phase 2 study in Lymphoma, B-CellNCT05463263
- Jun 30, 2028Primary completion: phase 2 study in Thrombocythemia, EssentialNCT06786234
TargetBeta
CTPS1 →read by rule
“An orally bioavailable, small molecule inhibitor of cytidine triphosphate synthase 1 (CTPS1), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06786234Thrombocythemia, Essential · France, United Kingdom | 2 | Recruiting | Jun 30, 2028 | 50 |
| NCT06297525Solid Tumor · United States, France, United Kingdom | 1 | Recruiting | Dec 2026 | 70 |
| NCT05463263Lymphoma, B-Cell · United States, France, United Kingdom | 2 | Recruiting | Dec 2026 | 180 |
How it is read
Names in the registry
- “STP938”, 3 entries
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 1 study
- Thrombocythemia, Essential, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.